Physician profile
Stephen G Smith
NPI 1235130022
$2,747.97
in general payments reported to CMS, 2019-2025
19 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $154 · 2021: $248 · 2022: $312 · 2023: $213 · 2024: $115 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,438 · Food and Beverage: $472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,437.68 |
| Food and Beverage | $472.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,517.61 | 2020-2025 | |
| Abbvie INC. | $258.62 | 2020-2025 | Orilissa, Lo Loestrin Fe |
| Pfizer INC. | $183.96 | 2019-2023 | |
| Exeltis, USA INC. | $133.62 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $122.65 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $108.82 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.75 | 2020-2023 | |
| Organon LLC | $69.48 | 2022-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $67.84 | 2022 | |
| Roche Diagnostics Corporation | $39.95 | 2019-2020 | |
| Aspira Women'S Health INC | $37.36 | 2021 | |
| Hologic Sales and Service, LLC | $26.15 | 2019-2022 | |
| Myovant Sciences INC. | $25.40 | 2021-2022 | |
| Axonics, INC. | $18.40 | 2023 | Axonics |
| Duchesnay USA Incorporated | $18.23 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $13.81 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $11.80 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.52 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.